Novo Nordisk begins construction of $223m manufacturing plant in Denmark
The company is investing DKK1.5bn ($223m) in this new facility, which is designed to produce active pharmaceutical ingredients for NovoSeven and future products to treat haemophilia. With the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.